TORONTO, March 9, 2023 /CNW/ - Medical Facilities Corporation ("Medical Facilities," "MFC," or the "Corporation") (TSX: DR), reported its financial results today for the fourth quarter and year ended December 31, 2022. All amounts are expressed in U.S. dollars unless indicated otherwise.
Q4 2022 Highlights (Compared to Q4 2021)
"While one-time items impacted our fourth quarter financial results, our core business remains strong, and we remain focused on delivering value to our stakeholders," said Jason Redman, President and CEO of Medical Facilities. "In the fourth quarter, surgical volumes increased at each of our four specialty surgical hospitals. We closed the book on UMASH, and we returned additional capital to our shareholders by repurchasing approximately 3.5 million common shares. We also aggressively pursued, and continue to pursue, opportunities to reduce expenses, which should help our fiscal 2023 results."
Financial Results
Financial Results | For the three months ended | For the year ended | ||||
December 31 | December 31 | |||||
(thousands of U.S. dollars, except | 2022 | % change | 2021 | 2022 | % change | 2021 |
Facility service revenue | 119,434 | 7.9 % | 110,677 | 424,551 | 6.5 % | 398,633 |
Government stimulus income | (12,335) | (314.8 %) | 5,742 | (10,162) | (177.6 %) | 13,099 |
Total revenue and other income | 107,099 | (8.0 %) | 116,419 | 414,389 | 0.6 % | 411,732 |
Consolidated operating expenses | 113,726 | 25.1 % | 90,917 | 379,450 | 13.5 % | 334,374 |
Income (loss) from operations | (6,627) | (126.0 %) | 25,502 | 34,939 | (54.8 %) | 77,358 |
Finance costs (net interest | 1,668 | 15.9 % | 1,439 | 5,731 | (5.5 %) | 6,064 |
Finance costs (changes in values | (9,098) | (681.7 %) | 1,564 | (859) | (104.2 %) | 20,280 |
Impairment loss (gain) on loan | (1,394) | (100.0 %) | - | 11,990 | 100.0 % | - |
Share of equity loss (income) in | 303 | 2,625.0 % | (12) | 574 | 359.2 % | 125 |
Income tax expense | 5,231 | 225.3 % | 1,608 | 5,208 | 18.5 % | 4,396 |
Net income (loss)2 | (3,337) | (116.0 %) | 20,903 | 12,295 | (73.6 %) | 46,493 |
Earnings (loss) per share | ||||||
Basic | (0.08) | (124.2 %) | 0.33 | (0.15) | (130.0 %) | 0.50 |
Diluted | (0.26) | (181.3 %) | 0.32 | (0.15) | (130.0 %) | 0.50 |
Reconciliation of Net Income | For the three months ended December 31 | For the year ended December 31 | ||||
(thousands of U.S. dollars, except | 2022 | % change | 2021 | 2022 | % change | 2021 |
Net income (loss) | (3,337) | (116.0 %) | 20,903 | 12,295 | (73.6 %) | 46,493 |
Income tax expense | 5,231 | 225.3 % | 1,608 | 5,208 | 18.5 % | 4,396 |
Share of equity loss (income) | 303 | 2,625.0 % | (12) | 574 | 359.2 % | 125 |
Finance costs (income) | (8,824) | (393.8 %) | 3,003 | 16,862 | (36.0 %) | 26,344 |
Depreciation and amortization | 5,359 | (16.9 %) | 6,451 | 20,763 | (22.4 %) | 26,769 |
EBITDA | (1,268) | (104.0 %) | 31,953 | 55,702 | (46.5 %) | 104,127 |
Impairment of goodwill, other | 16,549 | 100.0 % | - | 16,549 | 100.0 % | - |
Adjusted EBITDA | 15,281 | (52.2 %) | 31,953 | 72,251 | (30.6 %) | 104,127 |
Distributable Cash Flow | For the three months ended | For the year ended | ||||
December 31 | December 31 | |||||
(thousands of dollars, except per | 2022 | % change | 2021 | 2022 | % change | 2021 |
Cash available for distribution1 (C$) | 9,900 | (32.4 %) | 14,650 | 27,536 | (26.5 %) | 37,448 |
Distributions (C$) | 2,086 | (15.9 %) | 2,479 | 9,302 | 3.2 % | 9,011 |
Distributions per common share (C$) | 0.077 | (3.8 %) | 0.080 | 0.317 | 9.3 % | 0.290 |
Payout ratio1 | 21.2 % | 25.4 % | 16.9 % | 33.8 % | 40.2 % | 24.1 % |
On December 29, 2022, the Corporation sold its remaining 31.7% non-controlling ownership interest in UMASH for proceeds of $0.6 million, recording a pre-tax gain of $0.3 million in general and administrative expenses. Along with the sale of its equity interests, the Corporation also completed the full and final settlement of the loan receivable from UMASH for proceeds of $1.4 million, and, in connection with this transaction, recorded an impairment gain of the same amount on the loan receivable during the three months ended December 31, 2022, resulting in a net impairment loss of $12.0 million on the loan receivable for the year ended December 31, 2022.
Due to the denial and additional review of certain PPP loan forgiveness applications by the U.S. Small Business Administration ("SBA") in 2022, the Corporation no longer has reasonable assurance of meeting the forgiveness requirements for loans totaling $12.3 million. As a result, this amount has been reversed from government stimulus income for year ended December 31, 2022, and recorded as a liability under payor advances and government stimulus funds repayable as at December 31, 2022. There remains uncertainty over the final outcome as forgiveness applications for these PPP loans have not yet been definitively resolved. Management plans to vigorously pursue all reasonably available channels for reversing any denials. Any loans subsequently forgiven will result in a recognition of income and a reversal of the corresponding liability.
During the quarter, the Corporation purchased and cancelled 3,053,097 of its common shares at an aggregate purchase price of $25.5 million under a substantial issuer bid, and 433,300 of its common shares at an aggregate purchase price of $2.5 million under its normal course issuer bid programs.
During the quarter, MFC paid a quarterly cash dividend of C$0.0805 per common share (or C$0.322 per share on an annualized basis), which represented an annualized yield of 4.00% on the December 31, 2022, closing price of C$8.04 per common share.
On December 31, 2022, MFC had consolidated net working capital of $32.5 million, compared to $60.9 million on December 31, 2021.
MFC's financial statements and management's discussion and analysis, for the three-month and twelve-month periods ended December 31, 2022, will be filed on SEDAR at www.sedar.com on Thursday, March 9, 2023, and will also be available on Medical Facilities' website at www.medicalfacilitiescorp.ca.
Notice of Conference Call
Management of MFC will host a conference call today, March 9, 2023, at 8:30 am ET to discuss its fourth quarter financial results. All interested parties may join the conference call by dialing 416-764-8650 or 1-888-664-6383 approximately 15 minutes prior to the call to secure a line. To join the conference call without operator assistance, you may register and enter your phone number at https://emportal.ink/40SO72D to receive an instant automated call back.
A live audio webcast of the call will be available at https://bit.ly/MFC2022Q4. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived on MFC's website following the call date.
About Medical Facilities
Medical Facilities, in partnership with physicians, owns a diverse portfolio of highly rated, high-quality surgical facilities in the United States. MFC's ownership includes controlling interest in four specialty surgical hospitals located in Arkansas, Oklahoma, and South Dakota, and an ambulatory surgery center ("ASC") located in California. In addition, through a partnership with NueHealth LLC, Medical Facilities owns a controlling interest in five ambulatory surgery centers located in Michigan, Missouri, Nebraska, Ohio, and Pennsylvania. MFC also owns a non-controlling interest in an ASC in Missouri. The specialty surgical hospitals perform scheduled surgical, imaging, diagnostic and other procedures, including primary and urgent care, and derive their revenue from the fees charged for the use of their facilities. The ASCs specialize in outpatient surgical procedures, with patient stays of less than 24 hours. For more information, please visit www.medicalfacilitiescorp.ca.
Caution concerning forward-looking statements
Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. Some forward-looking statements may be identified by words like "may", "will", "anticipate", "estimate", "expect", "intend", or "continue" or the negative thereof or similar variations. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in Medical Facilities' filings with Canadian securities regulatory authorities such as legislative or regulatory developments, intensifying competition, technological change and general economic conditions. All forward-looking statements presented herein should be considered in conjunction with such filings. Medical Facilities does not undertake to update any forward-looking statements; such statements speak only as of the date made.
1 EBITDA, adjusted EBITDA, cash available for distribution and payout ratio are non-IFRS financial measures. While Medical Facilities believes that these measures are useful for the evaluation and assessment of its performance, they do not have any standard meaning prescribed by IFRS, are unlikely to be comparable to similar measures presented by other issuers, and should not be considered as alternatives to comparable measures determined in accordance with IFRS. For further information on these non-IFRS financial measures, including a reconciliation of each of these non-IFRS financial measures to the most directly comparable measure calculated in accordance with IFRS, please refer to Medical Facilities' most recently filed management's discussion and analysis, available on SEDAR at www.sedar.com. |
2 Net Income (Loss) is attributable to the owners of the Corporation and the non-controlling interest holders. |
Last Trade: | C$15.55 |
Daily Volume: | 4,343 |
Market Cap: | C$365.270M |
November 07, 2024 August 06, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB